TSE:NWH.UN

Northwest Health Prop Real Est Inv Trust (NWH.UN.TO)

5.66
-0.01 (0.18%)
as of Mar 10, 2026, 8:00:00 pm Market Open.
343 watching
0
Investor Insights
star iconJun 24, 2026, 12:00 am

This summary was created by AI, based on 10 opinions in the last 12 months.

Northwest Health Prop Real Est Inv Trust (NWH.UN-T) has been undergoing significant transformation under new management, particularly a CEO with experience from Brookfield. The company is in a restructuring phase, focusing on its North American assets while divesting from international operations, which many analysts view as a necessary step due to previous over-leverage. Despite challenges, including increased debt servicing costs and a forced asset sale, the company appears to have stabilized operations. Analysts note a stable yield over 6%, with some optimism surrounding its long-term potential, although many express caution regarding immediate price appreciation. Overall, the company's diverse portfolio of medical assets presents opportunity, but future growth may hinge on its execution of strategic initiatives.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
CNA, CEC
TOP PICK

It has a 6.2% yield and he doesn't usually put higher yielding stocks into the equity platforms. This one came from the income platform. It fell so fast because it was over-leveraged but has now sold some of its assets. It is building a base and appears to be breaking out so he has bought two of the three legs.                      Buy 0  Hold 5  Sell 0

(Analysts’ price target is $5.85)
DON'T BUY

Cut dividend in 2023. Global scale, so riskier than a traditional Canadian REIT. High occupancy of 96%. She's concerned about pricing pressure. These types of REITs tend to underperform in first stages of a recession. High debt load. Yield is 7%.

TOP PICK

Benefits from lower interest rates and a new CEO. Last year, they cut the dividend (which is safe as its payout ratio falls) and have sold $1.6 billion of assets. Their NAV is $9/share. Their properties serve healthcare, so are stable.

(Analysts’ price target is $5.71)
DON'T BUY

Its sector should be more resilient. Multiple jurisdictions, so multiple currencies and credit risks. Too much debt. Management overhaul. Going through strategic process. Distribution may be challenged. High risk. Better off elsewhere.

DON'T BUY

Strategic review. Management changes. Multiple jurisdictions globally, not very efficient for a Canadian REIT especially with the state of its balance sheet. Lots of headwinds on balance sheet and distribution coverage. High leverage, tight coverage. Good assets, but not lots of options. 

BUY

Large collection of healthcare real estate around the world. Inflation linked leases (good for income). Sticky tenants with doctors and healthcare. Problem is too much floating debt (higher interest rates). Recently replaced management team. Confident on business going forward. Expecting strength going forward. Book value is around $6-$7/share (trading around $4).  

DON'T BUY

It is effectively a REIT. It is down 50% over the past year, a function of interest rate pressure. They have cut their dividend.

PAST TOP PICK
(A Top Pick Dec 14/23, Down 43%)

Healthcare property business not performing as well as anticipating. Floating rate debt very hard on business with rising interest rates. CEO has since resigned. Would recommend holding going forward. 

SELL

Cut dividend. Healthcare properties around the world. Over-levered in a rising interest rate environment. Valuation imploded. Steer clear. Other distressed real estate ideas out there have more catalysts.

DON'T BUY

In flux. Founder/CEO left. Looking at strategic alternatives, possible asset sales. High leverage. A show-me story. Execution risk to sell assets and fix balance sheet in a difficult market.

DON'T BUY

Over-levered. Properties aren't performing as well. Geographic distribution requires them to be experts globally, which is a problem. CEO resigned, change in management. Whole sector's under stress, low quality gets hit harder.

HOLD

Recent cut in dividend. Not expecting any more dividend cuts going forward. Does not own shares at this time. If already own shares, would recommend keeping. 

DON'T BUY

Messy. Cut dividend by 55%. Good lesson on chasing a too-high dividend yield. 97% occupancy, but not enough to keep them out of financial difficulties. $4B of debt, more than 1/3 at floating rates. Giant "For sale" sign on it. Insider selling in January. Facing tax-loss selling if things don't turn around.

DON'T BUY

Lots of debt, operating in jurisdictions with currency risk. Bought stable, UK and US assets, but got caught offside with variable-rate debt cutting into cashflow. Cut distribution. Execution risk. Sold off, but don't add.

DON'T BUY
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research

The distribution cut was needed, but of course was fairly large (55%). The asset sales are a good start but challenges remain. The strategic review is only seven weeks old, but reading between the lines it sounds like there has not been huge interest yet. It is hard to endorse this right now. With higher rates and lower assets (from sales), growth will be hard to come by. We might be reluctant to sell it on the first trading day of this news, but we certainly think it can be 'targetted' for elimination from an investor's portfolio and used as a source of cash for other ideas. The stock will likely be in the penalty box for some time for multiple disappointments over the past year, with a business that is supposed to be more reliable and more predictable. We would not see solvency as an issue but it is just hard to like right now. 
Unlock Premium - Try 5i Free

Showing 16 to 30 of 133 entries